Test Catalog

Test Id : PNEFS

Neuroimmunology Antibody Follow-up, Serum

Useful For
Suggests clinical disorders or settings where the test may be helpful

Monitoring patients who have previously tested positive for one or more antibodies within the past 5 years in a Mayo Neuroimmunology Laboratory serum evaluation

Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test Id Reporting Name Available Separately Always Performed
GANG AChR Ganglionic Neuronal Ab, S No No
ACMFS AChR Modulating Flow Cytometry, S No No
AGNBS AGNA-1 Immunoblot, S No No
AINCS Alpha Internexin CBA, S No No
AMPCS AMPA-R Ab CBA, S No No
AMIBS Amphiphysin Immunoblot, S No No
AN1BS ANNA-1 Immunoblot, S No No
AN2BS ANNA-2 Immunoblot, S No No
AGN1S Anti-Glial Nuclear Ab, Type 1 No No
ANN1S Anti-Neuronal Nuclear Ab, Type 1 No No
ANN2S Anti-Neuronal Nuclear Ab, Type 2 No No
ANN3S Anti-Neuronal Nuclear Ab, Type 3 No No
CS2CS CASPR2-IgG CBA, S No No
CRMS CRMP-5-IgG, S No No
DPPCS DPPX Ab CBA, S No No
DPPTS DPPX Ab IFA Titer, S No No
DPPIS DPPX Ab IFA, S No No
GABCS GABA-B-R Ab CBA, S No No
GABIS GABA-B-R Ab IF Titer Assay, S No No
GFACS GFAP CBA, S No No
GFATS GFAP IFA Titer, S No No
GFAIS GFAP IFA, S No No
GRFCS GRAF1 CBA, S No No
GRFTS GRAF1 IFA Titer, S No No
GRFIS GRAF1 IFA, S No No
IGATS IgG Asialo GM1 Titer, S No No
IGG_A IgG Asialo. GM1 No No
IGDTS IgG Disialo GD1b Titer, S No No
IGG_D IgG Disialo. GD1b No No
IGMTS IgG Monos GM1 Titer, S No No
IG5CS IgLON5 CBA, S No No
IG5TS IgLON5 IFA Titer, S No No
IG5IS IgLON5 IFA, S No No
IMATS IgM Asialo GM1 Titer, S No No
IGM_A IgM Asialo. GM1 No No
IMDTS IgM Disialo GD1b Titer, S No No
IGM_D IgM Disialo. GD1b No No
IMMTS IgM Monos GM1 Titer, S No No
IGM_M IgM Monos. GM1 No No
ITPCS ITPR1 CBA, S No No
ITPTS ITPR1 IFA Titer, S No No
ITPIS ITPR1 IFA, S No No
LG1CS LGI1-IgG CBA, S No No
GL1CS mGluR1 Ab CBA, S No No
GL1TS mGluR1 Ab IFA Titer, S No No
GL1IS mGluR1 Ab IFA, S No No
VGKC Neuronal (V-G) K+ Channel Ab, S No No
NFHCS NIF Heavy Chain CBA, S No No
NIFTS NIF IFA Titer, S No No
NIFIS NIF IFA, S No No
NFLCS NIF Light Chain CBA, S No No
NMDCS NMDA-R Ab CBA, S No No
NMDIS NMDA-R Ab IF Titer Assay, S No No
CCPQ P/Q-Type Calcium Channel Ab No No
PC1BS PCA-1 Immunoblot, S No No
PCTBS PCA-Tr Immunoblot, S No No
PCABP Purkinje Cell Cytoplasmic Ab Type 1 No No
PCAB2 Purkinje Cell Cytoplasmic Ab Type 2 No No
PCATR Purkinje Cell Cytoplasmic Ab Type Tr No No
SRPIS SRP IFA Screen, S No No
SRPTS SRP IFA Titer, S No No
SRPBS SRP Immunoblot, S No No

Method Name
A short description of the method used to perform the test

AMPIS, AMPHS, AGN1S, ANN1S, ANN2S, ANN3S, CRMS, DPPTS, DPPIS, GABIS, GFATS, GFAIS, GRFTS, GRFIS, IG5TS, IG5IS, ITPTS, ITPIS, GL1TS, GL1IS, NIFTS, NIFIS, NMDIS, PCABP, PCAB2, PCATR, SRPIS, SRPTS: Indirect Immunofluorescence Assay (IFA)

AINCS, AMPCS, CS2CS, DPPCS, GABCS, GFACS, GRFCS, IG5CS, ITPCS, LG1CS, GL1CS, NFHCS, NFLCS, NMDCS: Cell Binding Assay (CBA)

CCPQ, GANG, VGKC: Radioimmunoassay (RIA)

ACMFS: Flow Cytometry (FACS)

IGATS, IGG_A, IGDTS, IGG_D, IGMTS, IMATS, IGM_A, IMDTS, IGM_D, IMMTS, IGM_M: Enzyme-linked Immunosorbent Assay (EIA)

AGNBS, AMIBS, AN1BS, AN2BS, PC1BS, PCTBS, SRPBS: Immunoblot (IB)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Neuroimmunology Ab Follow-up, S

Specimen Type
Describes the specimen type validated for testing

Serum

Ordering Guidance

This test is only appropriate for follow-up in patients who have previously tested positive in a serum test. If patients have not previously been positive in a serum test, order 1 of the following:

-PAVAL / Paraneoplastic, Autoantibody Evaluation, Serum

-GID2 / Autoimmune Gastrointestinal Dysmotility Evaluation, Serum

-DYS2 / Autoimmune Dysautonomia Evaluation, Serum

-DMS2 / Dementia, Autoimmune Evaluation, Serum

-ENS2 / Encephalopathy, Autoimmune Evaluation, Serum

-EPS2 / Epilepsy, Autoimmune Evaluation, Serum

-MDS2 / Movement Disorder, Autoimmune Evaluation, Serum

-MGLE / Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum

-MGMR / Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: 13- x 75-mm plastic screw-top vial.

Specimen Volume: 4 mL

Collection Instructions: Centrifuge within 2 hours. Aliquot and ship in 13- x 75-mm plastic screw-top vial.

Forms

If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

2 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
Frozen 28 days
Ambient 72 hours

Useful For
Suggests clinical disorders or settings where the test may be helpful

Monitoring patients who have previously tested positive for one or more antibodies within the past 5 years in a Mayo Neuroimmunology Laboratory serum evaluation

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Paraneoplastic autoimmune neurological disorders reflect a patient's humoral and cellular immune responses to cancer. The cancer may be new or recurrent, is usually limited in metastatic volume, and is often occult by standard imaging procedures. Autoantibodies specific for onconeural proteins found in the plasma membrane, cytoplasm, and nucleus of neurons or muscle are generated in this immune response and serve as serological markers of paraneoplastic autoimmunity. The most commonly recognized cancers in this context are small-cell lung carcinoma (SCLC), thymoma, ovarian (or related mullerian) carcinoma, breast carcinoma, and Hodgkin lymphoma. Pertinent childhood neoplasms recognized thus far include neuroblastoma, thymoma, Hodgkin lymphoma, and chondroblastoma. An individual patient's autoantibody profile can predict a specific neoplasm with 90% certainty, but not the neurological syndrome.

 

Four classes of autoantibodies are recognized in serum analysis:

-Neuronal nuclear (antineuronal nuclear antibody-type 1 [ANNA-1], ANNA-2, ANNA-3)

-Neuronal and muscle cytoplasmic (Purkinje cell cytoplasmic antibody, type 1 [PCA-1], PCA-2, PCA-Tr, collapsin response-mediator protein-5 [CRMP-5], amphiphysin, and striational)

-Glial nuclear (antiglial nuclear antibody)

-Plasma membrane cation channel antibodies (neuronal P/Q-type  and muscle acetylcholine receptor autoantibodies). These autoantibodies are potential effectors of neurological dysfunction.

 

Patients who are seropositive usually present with subacute neurological symptoms and signs. The patient may present with encephalopathy, cerebellar ataxia, myelopathy, radiculopathy, plexopathy, sensory, sensorimotor, or autonomic neuropathy, with or without coexisting evidence of a neuromuscular transmission disorder: Lambert-Eaton syndrome (LES), myasthenia gravis, or neuromuscular hyperexcitability. Initial signs may be subtle, but a subacute multifocal and progressive syndrome usually evolves. Sensorimotor neuropathy and cerebellar ataxia are common presentations, but the clinical picture in some patients is dominated by striking gastrointestinal dysmotility, limbic encephalopathy, basal ganglionitis, or cranial neuropathy (especially loss of vision, hearing, smell, or taste). Cancer risk factors include past or family history of cancer, history of smoking or social/environmental exposure to carcinogens. Early diagnosis and treatment of the neoplasm favor less neurological morbidity and offer the best hope for survival.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Test ID

Reporting Name

Methodology

Reference Value

GANG

AChR Ganglionic Neuronal Ab, S

Radioimmunoassay (RIA)

< or =0.02 nmol/L

ACMFS

AChR Modulating Flow Cytometry, S

Flow Cytometry (FACS)

Negative

AGNBS

AGNA-1 Immunoblot, S

Immunoblot (IB)

Negative

AINCS

Alpha Internexin CBA, S

Cell Binding Assay (CBA)

Negative

AMPCS

AMPA-R Ab CBA, S

CBA

Negative

AMPIS

AMPA-R Ab IF Titer Assay, S

Indirect Immunofluorescence Assay (IFA)

<1:120

AMPHS

Amphiphysin Ab, S

IFA

<1:240

AMIBS

Amphiphysin Immunoblot, S

IB

Negative

AN1BS

ANNA-1 Immunoblot, S

IB

Negative

AN2BS

ANNA-2 Immunoblot, S

IB

Negative

AGN1S

Anti-Glial Nuclear Ab, Type 1

IFA

<1:240

ANN1S

Anti-Neuronal Nuclear Ab, Type 1

IFA

<1:240

ANN2S

Anti-Neuronal Nuclear Ab, Type 2

IFA

<1:240

ANN3S

Anti-Neuronal Nuclear Ab, Type 3

IFA

<1:240

CS2CS

CASPR2-IgG CBA, S

CBA

Negative

CRMS

CRMP-5-IgG, S

IFA

<1:240

DPPCS

DPPX Ab CBA, S

CBA

Negative

DPPTS

DPPX Ab IFA Titer, S

IFA

<1:240

DPPIS

DPPX Ab IFA, S

IFA

<1:240

GABCS

GABA-B-R Ab CBA, S

CBA

Negative

GABIS

GABA-B-R Ab IF Titer Assay, S

IFA

<1:240

GFACS

GFAP CBA, S

CBA

Negative

GFATS

GFAP IFA Titer, S

IFA

<1:240

GFAIS

GFAP IFA, S

IFA

<1:240

GRFCS

GRAF1 CBA, S

CBA

Negative

GRFTS

GRAF1 IFA Titer, S

IFA

<1:240

GRFIS

GRAF1 IFA, S

IFA

<1:240

IGATS

IgG Asialo GM1 Titer, S

EIA

<1:16000

IGG_A

IgG Asialo. GM1

EIA

Negative

IGDTS

IgG Disialo GD1b Titer, S

EIA

<1:2000

IGG_D

IgG Disialo. GD1b

EIA

Negative

IGMTS

IgG Monos GM1 Titer, S

EIA

<1:2000

IG5CS

IgLON5 CBA, S

CBA

Negative

IG5TS

IgLON5 IFA Titer, S

IFA

<1:240

IG5IS

IgLON5 IFA, S

IFA

<1:240

IMATS

IgM Asialo GM1 Titer, S

EIA

<1:8000

IGM_A

IgM Asialo. GM1

EIA

Negative

IMDTS

IgM Disialo GD1b Titer, S

EIA

<1:2000

IGM_D

IgM Disialo. GD1b

EIA

Negative

IMMTS

IgM Monos GM1 Titer, S

EIA

<1:4000

IGM_M

IgM Monos. GM1

EIA

Negative

ITPCS

ITPR1 CBA, S

CBA

Negative

ITPTS

ITPR1 IFA Titer, S

IFA

<1:240

ITPIS

ITPR1 IFA, S

IFA

<1:240

LG1CS

LGI1-IgG CBA, S

CBA

Negative

GL1CS

mGluR1 Ab CBA, S

CBA

Negative

GL1TS

mGluR1 Ab IFA Titer, S

IFA

<1:240

GL1IS

mGluR1 Ab IFA, S

IFA

<1:240

VGKC

Neuronal (V-G) K+ Channel Ab, S

RIA

< or =0.02 nmol/L

NFHCS

NIF Heavy Chain CBA, S

CBA

Negative

NIFTS

NIF IFA Titer, S

IFA

<1:240

NIFIS

NIF IFA, S

IFA

<1:240

NFLCS

NIF Light Chain CBA, S

CBA

Negative

NMDCS

NMDA-R Ab CBA, S

CBA

Negative

NMDIS

NMDA-R Ab IF Titer Assay, S

IFA

<1:240

CCN

N-Type Calcium Channel Ab

RIA

< or =0.03 nmol/L

CCPQ

P/Q-Type Calcium Channel Ab

RIA

< or =0.02 nmol/L

PC1BS

PCA-1 Immunoblot, S

IB

Negative

PCTBS

PCA-Tr Immunoblot, S

IB

Negative

PCABP

Purkinje Cell Cytoplasmic Ab Type 1

IFA

<1:240

PCAB2

Purkinje Cell Cytoplasmic Ab Type 2

IFA

<1:240

PCATR

Purkinje Cell Cytoplasmic Ab Type Tr

IFA

<1:240

SRPIS

SRP IFA Screen, S

IFA

<1:240

SRPTS

SRP IFA Titer, S

IFA

<1:240

SRPBS

SRP Immunoblot, S

IB

 Negative

Interpretation
Provides information to assist in interpretation of the test results

Antibodies directed at onconeural proteins shared by neurons, muscle, and certain cancers are valuable serological markers of a patient's immune response to cancer. They are not found in healthy subjects and are usually accompanied by subacute neurological symptoms and signs. Several autoantibodies have a syndromic association, but no known autoantibody predicts a specific neurological syndrome. Conversely, a positive autoantibody profile has 80% to 90% predictive value for a specific cancer. It is not uncommon for more than one paraneoplastic autoantibody to be detected, each predictive of the same cancer.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test should only be utilized when the presence of paraneoplastic autoantibodies has been previously documented.

 

This test should not be requested in patients who have recently received radioisotopes, therapeutically, or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held one week and assayed if sufficiently decayed, or canceled if radioactivity remains.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

Lancaster E, Martinez-Hernandez E, Dalmau J: Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul 12;77(2):179-189

Method Description
Describes how the test is performed and provides a method-specific reference

Indirect Immunofluorescence Assay:

Before testing, patient's specimen is preabsorbed with liver powder to remove nonorgan-specific autoantibodies. After applying to a composite substrate of frozen mouse tissues (brain, kidney, and gut) and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the distribution and pattern of patient IgG binding.(Pittock SJ, Kryzer TJ, Lennon VA: Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004 Nov;56(5):715-719; Honorat JA, Komorowski L, Josephs KA, et al: IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neruol Neruoimmunol Neruoinflamm. 2017 Jul 18;4(5):e385. doi: 10.1212/NXI.0000000000000385)

 

Radioimmunoassay:

Goat-antihuman IgG and IgM is used as precipitant in all assays. Cation channel protein antigens are solubilized from neuronal or muscle membrane, in nonionic detergent, and complexed with a selective high-affinity ligand labeled with (125)I. (125)I-labelled recombinant human glutamic acid decarboxylase-65 (GAD65) antigen is used to confirm GAD65 autoantibody (when suspected from immunofluorescent staining pattern).(Griesmann GE, Kryzer TJ, Lennon VA: Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rose NR, Hamilton RG, et al, eds. Manual of Clinical and Laboratory Immunology. 6th ed. ASM Press, 2002:1005-1012; Walikonis JE, Lennon VA: Radioimmunoassay for glutamic acid decarboxylase [GAD65] autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc. 1998;73[12]:1161-1166; Jones AL, Flanagan EP, Pittock SJ, et al: Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol. 2015 Nov;72[11]:1304-1312. doi: 10.1001/jamaneurol.2015.2378)

 

Cell Binding Assay:

Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN, FA_112d-1_A_UK_C13, 02/2019)

 

Flow Cytometry:

This method uses flow cytometry to measure the loss of acetylcholine receptor (AChR) molecules expressed on the surface of live cells expressing AChR on the cell surface. The cell line used is an immortalized human rhabdomyosacroma cell line that expresses endogenous muscle-type nicotinic AChR on its surface. Cells are plated in a 96-well plate and cultured 72 hours prior to the addition of patient serum for an additional 18-22 hours to enable internalization of AChRs (modulation). Modulation is then stopped by placing cells on ice. The amount of remaining AChRs on the cell surface is measured by flow cytometry. On ice, cells are incubated with a recombinant rat monoclonal antibody against alpha-subunit of the AChR followed by a secondary goat anti-rat IgG antibody conjugated with APC. The amount of AChR on the cell surface is proportional to the median fluorescence intensity (MFI) of APC. To calculate the amount of modulation (i.e, % loss of AChR) the APC MFI is compared between cells treated with patient serum and cells treated with serum lacking AChR modulating antibodies. Background signal is established in each experiment utilizing cells stained with secondary antibody alone (no patient sera). The percent loss of AChR is calculated as 1-([Patient MFI-Background MFI]/[Negative calibrator MFI - Background MFI])*100%.(Unpublished Mayo method)

 

Immunoblot:

All steps are performed at ambient temperature (18-28 degrees C) utilizing the EUROBlot One instrument.

 

Diluted patient specimen (1:12.5) is added to test strips (strips containing recombinant antigen manufactured and purified using biochemical methods) in individual channels and incubated for 30 minutes. Positive samples will bind to the purified recombinant antigen and negative samples will not bind. Strips are washed to remove unbound antibodies and then incubated with antihuman IgG antibodies (alkaline phosphatase-labelled) for 30 minutes. The strips are again washed to remove unbound anti-human IgG antibodies and nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) substrate is added. Alkaline phosphatase enzyme converts the soluble substrate into a colored insoluble product on the membrane to produces a black band. Strips are digitized via picture capture on the EUROBlot One instrument and evaluated with the EUROLineScan software.(O'Connor K, Waters P, Komorowski L, et al: GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019 Apr 4;6[3]:e552. doi: 10.1212/NXI.0000000000000552)

 

Enzyme-linked Immunosorbent Assays:

Antiganglioside antibodies in specimens are detected by enzyme-linked immunosorbent assays (ELISA). Ganglioside antigens (GM1, Asialo GM1, and GD1b) adsorbed to wells of ELISA plates are incubated with patient's serum or controls. The plates are washed and alkaline phosphatase conjugated antihuman IgG or IgM antibodies (ie, secondary) are added in a second incubation. The wash step is repeated and enzyme substrate is added. Absorbance is measured and results are expressed as antibody titer, ie, the greatest dilution at which the absorbance of wells that contain patient sample is greater than 2.0 times the mean absorbance of normal sample tested simultaneously.(Taylor BV, Gross L, Windebank AJ: The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 1996 October;47:951-955; McKeon A, Lennon V, LaChance DH, et al: Striational antibodies in a paraneoplastic context. Muscle Nerve. 2013 Apr;47(4):585-587)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

GANG, VGKC, CCN, CCPQ:

Monday through Friday; 6 a.m., 8 a.m., 6 p.m.

Saturday, Sunday; 7 a.m.

 

ACMFS:

Monday, Wednesday, Saturday; 3 p.m.

 

AGNBS, AMIBS, AN1BS, AN2BS, PC1BS, PCTBS, SRPBS:

Monday through Friday; 6 p.m.

 

AINCS, NFHCS, NFLCS:

Tuesday, Thursday; 6 p.m.

 

AMPCS, CS2CS, DPPCS, GABCS, LG1CS, NMDCS:

Monday through Friday; 10 p.m.

Sunday; 3 p.m.

 

AMPIS, AMPHS, AGN1S, ANN1S, ANN2S, ANN3S, CRMS, DPPTS, DPPIS, GABIS, GFATS, GFAIS, GRFTS, GRFIS, IG5TS, IG5IS, ITPTS, ITPIS, GL1TS, GL1IS, NIFTS, NIFIS, NMDIS, PCABP, PCAB2, PCATR, SRPIS, SRPTS:

Monday through Friday; 5 a.m., 7 a.m., 5 p.m.

Saturday, Sunday; 6 a.m.

 

GFACS:

Monday, Wednesday, Friday; 6 p.m.

 

GRFCS, IG5CS, ITPCS, GL1CS:

Monday, Thursday; 6 p.m.

 

IGATS, IGG_A, IGDTS, IGG_D, IGMTS, IMATS, IGM_A, IMDTS, IGM_D, IMMTS, IGM_M:

Monday through Sunday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

Varies

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

28 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

83519-GANG (if appropriate)

86255-ACMFS (if appropriate)

84182-AGNBS (if appropriate)

86255-AINCS (if appropriate)

86255-AMPCS (if appropriate)

86256-AMPIS (if appropriate)

86255-AMPHS (if appropriate)

84182-AMIBS (if appropriate)

84182-AN1BS (if appropriate)

84182-AN2BS (if appropriate)

86255-AGN1S (if appropriate)

86255-ANN1S (if appropriate)

86255-ANN2S (if appropriate)

86255-ANN3S (if appropriate)

86255-CS2CS (if appropriate)

86255-CRMS (if appropriate)

86255-DPPCS (if appropriate)

86256-DPPTS (if appropriate)

86255-DPPIS (if appropriate)

86255-GABCS (if appropriate)

86256-GABIS (if appropriate)

86255-GFACS (if appropriate)

86256-GFATS (if appropriate)

86255-GFAIS (if appropriate)

86255-GRFCS (if appropriate)

86256-GRFTS (if appropriate)

86255-GRFIS (if appropriate)

83520-IGATS (if appropriate)

83516-IGG_A (if appropriate)

83520-IGDTS (if appropriate)

83516-IGG_D (if appropriate)

83520-IGMTS (if appropriate)

86255-IG5CS (if appropriate)

86256-IG5TS (if appropriate)

86255-IG5IS (if appropriate)

83520-IMATS (if appropriate)

83516-IGM_A (if appropriate)

83520-IMDTS (if appropriate)

83516-IGM_D (if appropriate)

83520-IMMTS (if appropriate)

83516-IGM_M (if appropriate)

86255-ITPCS (if appropriate)

86256-ITPTS (if appropriate)

86255-ITPIS (if appropriate)

86255-LG1CS (if appropriate)

86255-GL1CS (if appropriate)

86256-GL1TS (if appropriate)

86255-GL1IS (if appropriate)

83519-VGKC (if appropriate)

86255-NFHCS (if appropriate)

86256-NIFTS (if appropriate)

86255-NIFIS (if appropriate)

86255-NFLCS (if appropriate)

86255-NMDCS (if appropriate)

86256-NMDIS (if appropriate)

83519-CCN (if appropriate)

83519-CCPQ (if appropriate)

84182-PC1BS (if appropriate)

84182-PCTBS (if appropriate)

86255-PCABP (if appropriate)

86255-PCAB2 (if appropriate)

86255-PCATR (if appropriate)

86255-SRPIS (if appropriate)

86256-SRPTS (if appropriate)

84182-SRPBS (if appropriate)

LOINC® Information

Test Id Test Order Name Order LOINC Value
PNEFS Neuroimmunology Ab Follow-up, S 80615-8
Result Id Test Result Name Result LOINC Value
Result LOINC Value Tooltip
84300 Neuroimmunology Ab Follow-up, S 80615-8

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports